Mirum Pharmaceuticals, Inc. Website

Mirum Pharmaceuticals, Inc.

NasdaqGM-MIRM

Company Overview

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

  • Name

    Mirum Pharmaceuticals, Inc.

  • CEO

    Christopher Peetz

  • Website

    www.mirumpharma.com

  • Sector

    Biotechnology

  • Year Founded

    2018

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

What's happening

Nov 12, 2025 - Dec 12, 2025

Mirum Pharmaceuticals Faces Investor Concerns Amid Acquisition and Market Challenges

  • Mirum Pharmaceuticals announced a definitive agreement to acquire Bluejay Therapeutics for $620 million, raising investor concerns over financial implications.
  • The stock experienced a significant drop of 5.4% following the acquisition announcement, reflecting bearish sentiment among investors.
  • Despite reporting positive cash flow and projected revenues between $500 million and $510 million for the year, subsequent news led to further declines in share price.

Over the past month, Mirum Pharmaceuticals Inc (MIRM) saw a decline of 9.4%, significantly underperforming the S&P 500's return of 0.7%. A pivotal event during this period was the announcement of its acquisition deal with Bluejay Therapeutics, which includes substantial cash and stock components along with potential milestone payments based on sales performance. While this acquisition aims to enhance Mirum’s portfolio by adding brelovitug—a treatment for chronic hepatitis delta virus—it raised concerns regarding its financial ramifications among investors.

Following the acquisition news on December 8th, MIRM shares dropped sharply by 5.4%. This negative market reaction stemmed from apprehensions about both the deal itself and its financing structure through a concurrent private placement intended to raise approximately $200 million in gross proceeds. Additionally, insights from Evercore suggested potential challenges in achieving peak sales for treatments related to Fragile X syndrome despite an estimated market size exceeding $1 billion; these factors contributed further to investor unease.

Earlier in December, MIRM experienced some positive momentum when it reported being cash flow positive while projecting annual revenues between $500 million and $510 million. However, this optimistic outlook did not prevent subsequent declines after news emerged about enrolling participants in clinical studies targeting Fragile X syndrome alongside mixed results from ongoing trials involving other products like Livmarli and Volixibat.

Overall trends indicated that while there were moments of optimism—such as participation in investor conferences aimed at enhancing visibility—the weight of negative developments overshadowed these gains throughout December. As a result, MIRM not only fell behind its sector but also underperformed relative to broader market indices during this timeframe; specifically, it lagged behind the Health Care sector (XLV) by -11.3%.

NasdaqGM:MIRM